FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
h 0.5							

	Check this box if no longer subject to
	Section 16. Form 4 or Form 5
\cup	obligations may continue. See
	1 - 1 - 1 - 1 - 1 - 1 - 1 - 1

Instruc	tion 1(b).			Fil				Section 16(a 30(h) of the							.934							
							suer Name and Ticker or Trading Symbol rovate Therapeutics, Inc. [AVTE]									ionship of I all applicat Director		Perso	n(s) to Issu			
(Last)	•	First) Y SQ. 8TH FLO	(Middle)			ate (rliest Trans	acti	on (Mon	th/D	ay/Year)						Officer (g below)	give title		Other (below)	specify
(Street)	IDGE N	ЛA	02139		4. If	· Ame	endm	nent, Date o	of Or	riginal Fi	led (Month/Da	y/Year)		Line		Form file	d by One	Repor	Check App ting Persor	
(City)	(5	State)	(Zip)																		·	
		Т	able I - No	n-Deri	ativ	e S	ecu	rities Ac	cqu	iired, [Disp	posed o	of, or	Ве	nef	icially	y O	wned				
1. Title of S	Security (Ins	tr. 3)		2. Trans Date (Month/		Execution Date,			,	Transaction Dispose Code (Instr.			rities Acquired (A) or ed Of (D) (Instr. 3, 4 and				Beneficial Owned Fo		Fori		nership Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership
									Ī	Code	v	Amount		(A) or (D) Price				Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common	Stock			07/0	2/202	C 2,568,165 A				A		(1)		2,568,165		D ⁽²⁾						
Common	Stock			07/0	2/202	1				P		535,7	714 A \$14					3,103,879]) ⁽²⁾	
			Table II -					ties Acq warrants									Ow	ned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Y	C₀	nsactio	on etr.	Deriv Secu Acqu or Di	umber of vative urities uired (A) isposed of Instr. 3, 4 5)	Ex	Date Exe piration l onth/Day	Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		erlying	lying Deriva		Price of lerivative ecurity nstr. 5) Proce of lerivative derivative Securiti Benefici Owned Followir Reporte		10. Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
				Co	de V		(A)	(D)	Da Ex	te ercisable		xpiration ate	Title		Amount or Number of Shares				Transaction((Instr. 4)			
Series A Preferred Stock	(1)	07/02/2021		(7,976,754		(1)		(1)	Comm		2,5	68,16	5	(1)	0		D ⁽²⁾	
		Reporting Person* and XII, L.P.																				
(Last)	CHNOLOG	(First) Y SQ. 8TH FLO	(Middle	e)																		
(Street)						_																

1. Name and Address of Reporting Person* Atlas Venture Fund XII, L.P.									
(Last)	(First)	(Middle)							
300 TECHNOLOGY SQ. 8TH FLOOR									
(Street)									
CAMBRIDGE	MA	02139							
(City)	(State)	(Zip)							
Name and Address of Reporting Person* Atlas Venture Associates XII, L.P.									
(Last)	(First)	(Middle)							
300 TECHNOLOGY SQ. 8TH FLOOR									
(Street)									
CAMBRIDGE	MA	02139							
(City)	(State)	(Zip)							
1. Name and Address of Reporting Person* <u>Atlas Venture Associates XII, LLC</u>									
(Last)	(First)	(Middle)							
300 TECHNOLOGY SQ. 8TH FLOOR									
(Street)									
CAMBRIDGE	MA	02139							
(City)	(State)	(Zip)							

Explanation of Responses:

on a one-for-3.1060103 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.

2. The shares are held directly by Atlas Venture Fund XII, L.P. ("Atlas Fund XII"). The general partner of Atlas Fund XII is Atlas Venture Associates XII, L.P. ("AVA XII LP"). Atlas Venture Associates XII, L.P. ("AVA XII LP."). Atlas Venture Associates XII, L.P. ("AVA XII LP."). Atlas Venture Associates XII, L.C. ("AVA XII LP. Each of AVA XII LP. Each of AVA XII LP and AVA XII LC disclaim Section 16 beneficial ownership of the securities owned by Atlas Fund XII, except to the extent of its pecuniary interest therein, if any.

Atlas Venture Fund XII, L.P. By: Atlas Venture Associates XII, L.P., Its: General Partner By: 07/06/2021

Atlas Venture Associates XII,

LLC, Its General Partner, By: /s/

Ommer Chohan

Atlas Venture Associates XII,

L.P., By: Atlas Venture Associates XII, LLC, Its General 07/06/2021

Partner, By: /s/ Ommer Chohan

Atlas Venture Associates XII, LLC, By: /s/ Ommer Chohan

07/06/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.